文献速递老年精神心境障碍会诊联络精神医学

延缓重性抑郁障碍与轻度认知障碍患者的认知衰退:一项随机临床试验

Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

这项在加拿大5家学术医院开展的随机临床试验纳入375名缓解期重性抑郁障碍(rMDD)和/或轻度认知障碍(MCI)的老年人,评估认知矫正(CR)联合经颅直流电刺激(tDCS)的疗效。中位随访48.3个月时,CR联合tDCS减缓了认知衰退(第60个月校正z评分差值0.21,95%CI 0.07~0.35,LRT P=0.006),但未急性改善认知,对延缓进展至MCI或痴呆的效果较弱且未达统计学显著(HR 0.66,95%CI 0.40~1.08,P=0.10)。

要点

  • CR联合tDCS减缓rMDD或MCI老年人的认知衰退,第60个月校正z评分差值0.21(95%CI 0.07~0.35,LRT P=0.006)。
  • 第2个月认知急性改善未达统计学显著(校正z评分差值0.06,95%CI -0.006~0.12)。
  • 延缓进展至MCI或痴呆的效果较弱且未达统计学显著(HR 0.66,95%CI 0.40~1.08,P=0.10)。

核心结论

  • CR联合tDCS均靶向前额叶皮层,能有效减缓有认知衰退风险的老年人的认知衰退,尤其是rMDD(伴或不伴MCI)患者和阿尔茨海默病遗传风险低者。

研究设计与样本

  • 随机临床试验,在加拿大安大略省多伦多的5家学术医院开展。
  • 参与者为rMDD(伴或不伴MCI,年龄≥65岁)或MCI无rMDD(年龄≥60岁)的老年人。
  • 486名老年人提供知情同意,375名(rMDD、MCI或两者兼有)接受至少1次干预,平均(SD)年龄72.2(6.4)岁,女性232名(62%),男性143名(38%)。
  • 评估在基线、第2个月及从基线起每年进行,持续3至7年。

主要发现

  • 中位随访48.3个月(范围2.1~85.9)内,CR联合tDCS减缓rMDD或MCI老年人的认知衰退,第60个月校正z评分差值(活性-假刺激)0.21,95%CI 0.07~0.35,LRT P=0.006。
  • 预设主要分析中,CR联合tDCS未急性改善认知,第2个月校正z评分差值(活性-假刺激)0.06,95%CI -0.006~0.12。
  • CR联合tDCS延缓从正常认知进展至MCI或从MCI进展至痴呆的效果较弱且未达统计学显著(HR 0.66,95%CI 0.40~1.08,P=0.10)。
  • 预设分析显示执行功能(LRT P=0.04)和言语记忆(LRT P=0.02)存在治疗效应,并与诊断(P=0.01)和APOE ε4(P<0.001)存在交互作用,rMDD患者和APOE ε4非携带者中效应更大。

关键数值与推荐

  • 主要结局为全局复合认知评分变化。
  • 次要结局包括6个认知域变化、诊断的调节效应、APOE ε4状态的调节效应、第2个月复合评分变化及随时间进展至MCI或痴呆。
  • 干预方案为CR联合tDCS(活性)或假刺激联合假CR,每周5天共8周,随后每年2次5天加强治疗及每日居家CR或假CR。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Older adults with major depressive disorder (MDD) or mild cognitive impairment (MCI) are at high risk for cognitive decline. OBJECTIVE: To assess the efficacy of cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) targeting the prefrontal cortex in slowing cognitive decline, acutely improving cognition, and reducing progression to MCI or dementia in older adults with remitted MDD (rMDD), MCI, or both. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted at 5 academic hospitals in Toronto, Ontario, Canada. Participants were older adults who had rMDD (with or without MCI, age ≥65 y) or MCI without rMDD (age ≥60 y). Assessments were made at baseline, month 2, and yearly from baseline for 3 to 7 years. INTERVENTIONS: CR plus tDCS (hereafter, active) or sham plus sham 5 days a week for 8 weeks followed by twice-a-year 5-day boosters and daily at-home CR or sham CR. MAIN OUTCOMES AND MEASURES: The primary outcome was change in global composite cognitive score. Secondary outcomes included changes in 6 cognitive domains, moderating effect of the diagnosis, moderating effect of APOE ε4 status, change in composite score at month 2, and progression to MCI or dementia over time. RESULTS: Of 486 older adults who provided consent, 375 (with rMDD, MCI, or both) received at least 1 intervention session (mean [SD] age, 72.2 [6.4] years; 232 women [62%] and 143 men [38%]). Over a median follow-up of 48.3 months (range, 2.1-85.9), CR and tDCS slowed cognitive decline in older adults with rMDD or MCI (adjusted z score difference [active - sham] at month 60, 0.21; 95% CI, 0.07 to 0.35; likelihood ratio test [LRT] P = .006). In the preplanned primary analysis, CR and tDCS did not improve cognition acutely (adjusted z score difference [active - sham] at month 2, 0.06, 95% CI, -0.006 to 0.12). Similarly, the effect of CR and tDCS on delaying progression from normal cognition to MCI or MCI to dementia was weak and not significant (hazard ratio, 0.66; 95% CI, 0.40 to 1.08; P = .10). Preplanned analyses showed treatment effects for executive function (LRT P = .04) and verbal memory (LRT P = .02) and interactions with diagnosis (P = .01) and APOE ε4 (P < .001) demonstrating a larger effect among those with rMDD and in noncarriers of APOE ε4. CONCLUSIONS AND RELEVANCE: The study showed that CR and tDCS, both targeting the prefrontal cortex, is efficacious in slowing cognitive decline in older adults at risk of cognitive decline, particularly those with rMDD (with or without MCI) and in those at low genetic risk for Alzheimer disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02386670.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rajji TK, Bowie CR, Herrmann N, et al. Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 39476073. doi:10.1001/jamapsychiatry.2024.3241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。